Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin, David H Miller, Mark S Freedman, Bruce AC Cree, Jerry S Wolinsky, Howard Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard MJ Uitdehaag, Martin Merschhemke, Bingbing Li, Norman Putzki, Fonda C Liu, Dieter A Haering, Ludwig Kappos
The Lancet | ELSEVIER SCIENCE INC | Published : 2016
Awarded by National Institute for Health Research
Novartis Pharma AG.Novartis Pharma AG (Basel, Switzerland) supported this study. Central MRI analysis was done at the Queen Square MS Centre, UCL Institute of Neurology (London, UK). Members of the central MRI analysis team were: David G MacManus, Tarek A Yousry, Claudia A M Wheeler-Kingshott, Ozgur Yaldizli, Jon Stutters, Catherine M Dalton, Virginia Santana, Almudena Garcia-Gomez, Carolina Crespo, David H Miller. The Queen Square MS Centre is supported by the UK MS Society and the UCL-UCLH joint Biomedical Research Centre. We thank the patients who participated in the study; the study-site personnel; Ana de Vera, Goeril Karlsson and the Novartis clinical team; and Katy Demery (Novartis) and Paul Coyle (Western Edge Medical Communications Ltd) for editorial assistance.